For more than three decades, one obscure provision of the Food, Drug and Cosmetic Act has created outsized uncertainty for the dietary supplement marketplace. “Drug preclusion” — originally intended as a narrow protection to prevent supplement companies from appropriating pharmaceutical innovation — has instead evolved into a source of regulatory instability, commercial risk and consumer confusion.
The Council for Responsible Nutrition (CRN) is planning to promote legislative reforms to modernize this provision to reflect the realities of two adjacent industries. These proposed updates would not weaken the Food and Drug Administration (FDA) authority. They would not allow irresponsible products onto the market. And they would not diminish incentives for pharmaceutical research.
What they would do is restore balance — clarifying how two legitimate, science-based health sectors can coexist under a predictable regulatory framework that serves consumers.
In short, this is modernization, not deregulation.
Moving drug preclusion where it belongs: enforcement, not definition
One of the most consequential — though technical — reforms would relocate drug preclusion from the dietary supplement statutory definition section to the prohibited acts section of the Federal Food, Drug and Cosmetic Act (FDCA).
That distinction matters enormously.
Today, drug preclusion is embedded within the definition of a dietary supplement, meaning a product’s legal identity can effectively disappear based on facts the marketplace may never see — including confidential pharmaceutical filings. This structure has allowed regulatory determinations to ripple unpredictably across labeling, safety reviews, new dietary ingredient (NDI) notifications and enforcement decisions.
Under CRN’s proposal, drug preclusion would instead function as what it logically is: an enforcement determination.
If FDA concludes that marketing an ingredient as a supplement violates the law, it can act — clearly and directly. This approach would give FDA a more transparent legal basis for action while removing collateral consequences unrelated to safety.
Relocating the provision would reduce years of interpretive ambiguity.
Restoring the original intent of the law
Congress did not intend drug preclusion to grant pharmaceutical companies control over substances that may function differently depending on how they are used. Yet current interpretation has often had that effect.
CRN’s proposed reform would limit preclusion to drugs intended for oral ingestion — the same route used by dietary supplements.
This is common sense. An intravenously infused hospital drug, an inhaled therapy or a transdermal treatment is not competing with an orally consumed wellness product that provides nutritional support. Different routes of administration mean different physiological interactions, different consumer uses and often different health purposes.
Preclusion should prevent substitution — not innovation in adjacent categories.
Ending the ‘race to the filing cabinet’
CRN’s reform also addresses one of the most troubling inequities in the current framework: reliance on confidential Investigational New Drug (IND) application dates.
Under FDA’s current interpretation, a company can file an IND, keep it confidential and years later assert that the filing date blocks a supplement that has been lawfully marketed — even though the supplement company had no way to know the filing existed when it began marketing an ingredient as a supplement. The recent situation involving nicotinamide mononucleotide (NMN) illustrates exactly how disruptive this dynamic can be.
That is not intellectual property protection; it is regulatory ambush.
The legislative proposal would require meaningful clinical development of the drug — such as advancement into Phase 2 trials — before preclusion attaches. Early exploratory research would no longer be sufficient to eliminate an ingredient from supplement use. Pharmaceutical innovation would remain protected, but speculative filings would no longer create invisible barriers to market entry.
Transparency promotes both fairness and investment.
Protecting longstanding ingredients and consumer trust
Thirty years after passage of the Dietary Supplement Health and Education Act of 1994 (DSHEA), consumers reasonably assume that long-marketed ingredients are stable parts of the supplement landscape. Yet companies still face the risk that decades-old products could disappear because of dormant pharmaceutical research conducted before 1994.
The reform would confirm that ingredients marketed before DSHEA’s enactment are not subject to preclusion — consistent with Congress’s intent that “grandfathered” ingredients remain lawful.
Similarly, if a drug sponsor abandons development for seven years, exclusivity would end. A monopoly cannot exist without an actual product serving patients. This approach mirrors exclusivity periods already recognized elsewhere in drug law.
Incentives would remain — a perpetual monopoly would not.
Giving FDA tools to act — and act quickly
Ironically, current law can leave FDA constrained even when it has completed a safety review. The experience with N-acetyl cysteine demonstrated that initiating a full rulemaking simply to recognize an exception can be time-consuming, cumbersome and impractical.
The proposal would allow FDA to grant exceptions through administrative order.
This preserves scientific oversight while allowing the agency to respond more efficiently to real-world regulatory needs. Efficient government is not weaker government — it is more credible government.
Creating due process and ending regulatory limbo
Perhaps the greatest economic damage caused by drug preclusion has not been formal enforcement actions but prolonged uncertainty.
FDA may communicate a preclusion position through warning letters, inspection observations, NDI objections or public advisories — all of which the agency argues are not final agency action. If an FDA action is not considered final by a court, companies are constrained from challenging these positions. Retailers respond conservatively. Products disappear overnight. Consumers are left confused. All without appropriate due process and judicial review for the dietary supplement company.
The reform would permit judicial review of preclusion determinations.
This would not undermine FDA authority; it would strengthen it. Agency decisions grounded in science and statute should withstand scrutiny, and companies deserve a defined path to resolution rather than indefinite regulatory limbo.
Predictability supports compliance.
Establishing a science-based framework
Finally, the proposal would direct FDA — and courts — to evaluate a defined set of scientific factors when determining whether a drug and a supplement are the same “article,” including:
Biological mechanism of action.
Composition and concentration.
No single factor would be determinative. Together, they would provide a balanced, science-based framework for analysis.
That is what modern regulatory policy should look like: evidence-based decision-making instead of categorical assumptions.
Why this matters
The supplement and pharmaceutical industries are not adversaries. They serve different but complementary roles across the continuum of health — prevention, maintenance and treatment.
Consumers move seamlessly along that continuum every day.
But innovation cannot thrive in uncertainty. Retailers cannot plan around invisible rules or hidden triggers. Responsible companies cannot invest when compliance hinges on confidential filings and shifting interpretations.
These proposed reforms would preserve incentives for drug development while protecting access to safe nutritional products. They would strengthen FDA’s enforcement authority while adding transparency. They would promote innovation without sacrificing safety.
Most importantly, they would provide what the marketplace has lacked for years: rules that are understandable before — not after — a product reaches consumers.
For a mature industry serving millions of Americans who proactively support their health, that certainty is not a luxury. It is essential infrastructure.
And for consumers, clarity in regulation ultimately means confidence in products — the foundation of both public health and a functioning marketplace.
